You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company said it will look to obtain regulatory approval in additional countries to accelerate the analyzer's market introduction in Asia and Africa.
Through its Access to COVID-19 Tools-Accelerator program, or ACT-A, WHO hopes to quickly identify and scale up high performing rapid antigen-based diagnostics.
The company will donate full laboratory set-ups to the effort and provide training and education to implement screening programs.
The point-of-care system is designed to measure glycated hemoglobin levels in whole blood for use in the monitoring and management of diabetes.
Validation for the BioSure COVID-19 Antibody Self-Test, which provides results in 10 minutes and requires no training, is currently underway, the firms said.
The agreement reflects Oncocyte's strategy to establish distribution partners with existing oncology channels to extend the reach of its tests globally.
The laboratory test was validated by Mologic in collaboration with the Liverpool School of Tropical Medicine and St George's, University of London.
The Foundation for Innovative New Diagnostics is tracking commercial coronavirus diagnostics development project, with the goal of guiding procurement.
A four-year, $5.5 million program will assess whether circulating cell-free DNA testing can improve diagnosis and outcomes for a type of EBV-associated cancer.
The partners are validating three rapid diagnostic test prototypes prior to initiating a trial in the Democratic Republic of the Congo during March 2020.